Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study

被引：14

作者：

Lewis, Joseph M. ^{[1
,10
]}

Smith, Colette ^{[2
]}

Torkington, Adele ^{[3
]}

Davies, Craig ^{[3
]}

Ahmad, Shazaad ^{[3
]}

Tomkins, Andrew ^{[3
]}

Shaw, Jonathan ^{[4
]}

Kingston, Margaret ^{[4
]}

Muqbill, Ghadeer ^{[5
]}

Hay, Philip ^{[5
]}

Mulka, Larissa ^{[6
]}

Williams, Deborah ^{[6
]}

Waters, Laura ^{[7
]}

Brima, Nataliya ^{[7
]}

Marshall, Neal ^{[8
]}

Johnson, Margaret ^{[8
]}

Chaponda, Mas ^{[1
]}

Nelson, Mark ^{[9
]}

机构：

[1] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[2] UCL, London, England

[3] North Manchester Gen Hosp, Manchester, Lancs, England

[4] Manchester Ctr Sexual Hlth, Manchester, Lancs, England

[5] St George Hosp, London, England

[6] Brighton & Sussex Univ Hosp, Brighton, E Sussex, England

[7] Mortimer Market Ctr, London, England

[8] Royal Free London, London, England

[9] Chelsea & Westminster Hosp, London, England

[10] Wellcome Trust Liverpool Glasgow Ctr Global Hlth, Block E Royal Infirm Complex,70 Pembroke Pl, Liverpool L69 3GF, Merseyside, England

来源：

JOURNAL OF INFECTION | 2017年 / 74卷 / 04期

基金：

英国惠康基金;

关键词：

HIV; Antiretroviral therapy; ART; Persistence; Adherence; INHIBITOR THERAPY; ADHERENCE; DISCONTINUATION; OUTCOMES; INTERVENTIONS;

D O I：

10.1016/j.jinf.2017.01.012

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: Persistence with an antiretroviral therapy (ART) regimen for HIV can be defined as the length of time a patient remains on therapy before stopping or switching. We aimed to describe ART persistence in treatment naive patients starting therapy in the United Kingdom, and to describe differential persistence by treatment regimen. Methods: We performed a retrospective cohort study at eight UK centres of ART-naive adults commencing ART between 2012 and 2015. Aggregate data were extracted from local treatment databases. Time to discontinuation was compared for different third agents and NRTI backbones using incidence rates. Results: 1949 patients contributed data to the analysis. Rate of third agent change was 28 per 100 person-years of follow up [95% CI 26-31] and NRTI backbone change of 15 per 100 person-years of follow up [95% CI 14-17]). Rilpivirine, as co-formulated rilpivirine/tenofovir/emtricitabine had a significantly lower discontinuation rate than all other third agents and, excluding single tablet regimens, co-formulated tenofovir/emtricitabine had a significantly lower discontinuation rate than co-formulated abacavir/lamivudine. The reasons for discontinuation were not well recorded. Conclusions: Treatment discontinuation is not an uncommon event. Rilpivirine had a significantly lower discontinuation rate than other third agents and tenofovir/emtricitabine a lower rate than co-formulated abacavir/lamivudine. (C) 2017 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.

引用

页码：401 / 407

页数：7

共 11 条

[1] Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression [J].